Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06963814

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

A Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose-Escalation and Multiple Cohort Dose Expansion Phase 1b Clinical Trial

Sponsor: HC Biopharma Inc.

Conditions Advanced Cancer

Interventions HC006 KEYTRUDA ®( Pembrolizumab)

Updated 2 times since 2025 Last updated: Jul 14, 2025 Started: Jul 4, 2025 Primary completion: May 30, 2026 Completion: May 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Cancer, this trial is actively recruiting participants. The trial is conducted by HC Biopharma Inc. and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Aug 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HC Biopharma Inc.

Data source: HC Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China